On March 13, 2024, the company received a letter from Nasdaq indicating that the company has a cure period in order to regain compliance as follows:
- until the earlier of the company's next annual shareholders' meeting or November 28, 2024; or
- if the next annual shareholders' meeting is held before May 27, 2024, then the company must evidence compliance no later than May 27, 2024.
The company intends to fill the vacancy on the company's board of directors and audit committee with a qualified individual who meets the criteria of the Nasdaq listing rules in advance of the compliance deadline.